BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance

U.S. Markets closed

Bristol-Myers Squibb Company (BMY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
49.23-6.26 (-11.28%)
At close: 4:00PM EST
People also watch
MRKLLYABTPFEJNJ
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close55.49
Open50.01
Bid0.00 x
Ask0.00 x
Day's Range48.92 - 50.69
52 Week Range48.92 - 77.12
Volume77,021,216
Avg. Volume10,058,274
Market Cap82.27B
Beta0.98
PE Ratio (TTM)24.63
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.56 (2.78%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Why Rite Aid, Bristol-Myers Squibb, and TransDigm Group Slumped Today
    Motley Fool6 hours ago

    Why Rite Aid, Bristol-Myers Squibb, and TransDigm Group Slumped Today

    Despite a rising market, these stocks fell. Find out why.

  • Reuters8 hours ago

    Merck, Bristol-Myers agree to settle Keytruda patent suit

    Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda. Merck will make an initial payment of $625 million to Bristol and Japan's Ono. The company will also pay a 6.5 percent royalty rate on Keytruda sales from January 2017 to December 2023, and a 2.5 percent rate for the subsequent three years.

  • Barrons.com8 hours ago

    The Biggest Loser: Bristol-Myers Sinks 11%

    Bristol-Myers Squibb (BMY) tumbled to the bottom of the S&P 500 today after the company said it would not try to get a quick approval from the FDA for its lung cancer treatment. Bristol-Myers Squibb dropped 11% to $49.23, while the S&P 500 advanced 0.3% to 2,271.31. Morgan Stanley's David Risinger and team call is a "perplexing disappointment." They explain why: Negative signal about the profile of combo in lung cancer.